Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu • (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.
Neuron-derived microRNAs obtained from blood samples may correlate with treatment response and could aid the search for new therapeutics.
UAB pathologist also leads a trainee in producing software to improve the quality and efficiency of perinatal autopsies.
Increased risk of major adverse cardiac events after the later surgery persists for one year.
Between-hospital variations in active treatment explain much of the difference seen in infants born at 22 to 24 weeks of gestation.
The protective effect is achieved by reducing acute inflammation in the spleen and the left ventricle of the heart.
UAB discovery gives better understanding of and potential therapies for septic shock and reperfusion injuries.
Elevated PARP1 polymerase in HER2+ breast cancer may confer susceptibility to PARP inhibitor drugs.
The ability to build a mimic of the interferon-interferon receptor complex allows a hunt for unique monoclonal antibodies.
The runx2 master transcription factor functions differently in chondrocytes and osteoblasts, two key cells in bone formation.
Similar to the ancient Greek legend of the Trojan horse, platelets in a transgenic mouse deliver a life-saving enzyme.